Cytokinetics, Incorporated (CYTK) shares fell 0.2% to $62.79 as of October 13, 2026, a slight decline from the prior close of $62.91. BestStocks flagged the session as a major change for CYTK. The move is tied to company news. Below, we break down what changed for CYTK, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
Company News
Cytokinetics presented additional ACACIA-HCM trial data on aficamten's exercise performance, dosing, and safety in non-obstructive HCM. Expanded efficacy and safety data strengthens aficamten's regulatory profile and commercial potential in HCM treatment market.
This summary describes the catalyst and move as first detected on Oct 12, 2026, 4:49 PM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
NewsWeak confidence
Rel. volume
0.6×
Below Avg
Vs peers
—
No comparable peers
Market cap
$7.8B
NASDAQ
Analyst target
$115
+82.4% vs price
Price chart
Sep 14 – Oct 12
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Cytokinetics, Incorporated investors
For Cytokinetics, Incorporated investors, the recent signals add up to a bearish shift. On the constructive side: CYTK moved +3.08% from its $78.94 open to a $81.37 close on 2026-08-06. Weighing against that: Material negative event; Negative session, down 0.2%. Wall Street's consensus price target sits at $114.56, implying +82.4% upside from $62.79. BestStocks rates the overall signal quality weak (31/100). With earnings roughly 22 days out, the next report is the most likely near-term test of the move.
CYTK price reaction
CYTK last traded at $62.79, down $0.12 (-0.19%) from the previous close of $62.91. The session traded on 0.6× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $61.12 and $72.45, and it currently sits about 15% of the way up that band.
Bullish and bearish analyst opinions on Cytokinetics, Incorporated (CYTK)
The consensus analyst price target on Cytokinetics, Incorporated (CYTK) is $114.56, 82.4% above the recent $62.79. Over the past 90 days analysts logged 0 upgrades, 8 maintains, and 0 downgrades. Here is how the bullish and bearish cases on CYTK line up.
▲ The bullish case
+Wall Street's consensus price target of $114.56 implies +82.4% upside from $62.79.
+The Street's most bullish target is $140.00 (+123.0%).
+CYTK moved +3.08% from its $78.94 open to a $81.37 close on 2026-08-06.
▼ The bearish case
−Material negative event.
−Negative session, down 0.2%.
−Cytokinetics, Incorporated moved -4.06% intraday from $72.45 to $69.51.
Bull vs bear balanceBearish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 12, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Article compares Cytokinetics and Zai Lab across profitability, valuation, dividends, and institutional ownership metrics.
Material / Earnings2026-10-08+1.5%
Cytokinetics, Incorporated (CYTK) moved +2.82% from $60.31 to $62.01 on 2026-10-08. We checked news, earnings announcements, analyst updates, filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average, indicating the move was not accompanied by unusual trading activity.
Cytokinetics fell 3.01% to $63.62 following a Wall Street Zen analyst downgrade from hold to sell, citing widening net losses driven by heavy commercialization and R&D spending against early MYQORZO commercial revenues (web_catalyst). Volume of 936k shares (1.34x intraday average) reflects normal trading intensity; the stock trades below its 50- and 200-day moving averages amid sector-wide biotech caution.
News2026-10-02-0.0%
Cytokinetics announced four presentations at HFSA 2026, including two late-breaking clinical research presentations.
News2026-09-30+0.4%
Cytokinetics launches ASPEN-HCM, a multi-center real-world study tracking MYQORZO safety and effectiveness in obstructive hypertrophic cardiomyopathy.
Cytokinetics, Incorporated moved -3.62% intraday from $67.59 to $65.14. 📉 Cytokinetics (CYTK) stock has experienced downward pressure and recent insider selling, following a broader market reassessment of its Phase 3 trial data for aficamten presented at the European Society of Cardiology (ESC) Congress. ### ⚠️ Recent Insider Selling - Executive sales: EVP Fady Ibrahim Malik sold 3,500 shares. - CEO transactions: The CEO also offloaded a significant block of shares valued at over $6.7 million. - Market signal: Heavy insider selling often prompts cautious near-term sentiment among retail investors. ### 🔎 Post-ESC Data Reassessment - Trial results: Aficamten hit endpoints in non-obstructive hypertrophic cardiomyopathy (nHCM). - Safety questions: Analysts noted a small number of severe/serious heart failure events during evaluation. - Expectation gap: Some investors anticipated an even larger immediate catalyst from the data readout. ### 📊 Financial Foundations & Context - Cash burn: High R&D spending yields negative free cash flow typical of clinical-stage biotech. - Valuation gap: Long-term consensus analyst targets remain higher than current trading levels despite the pullback. If you hold or are looking to trade CYTK, let me know: - Are you trading
Cytokinetics, Incorporated moved -4.06% intraday from $72.45 to $69.51. Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript: Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript [2026-09-14]
Material / Earnings2026-09-08+3.6%
Cytokinetics, Incorporated (CYTK) moved +4.09% from $72.39 to $75.35 on 2026-09-08. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.
In-depth CYTK event analyses
Permanent, dated analyses of CYTK's most significant sessions.
Why did Cytokinetics, Incorporated (CYTK) stock move?
CYTK fell 0.2% to $62.79. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did CYTK stock fall?
CYTK lost 0.19% ($0.12) versus the prior close of $62.91, last trading at $62.79 on 0.6× average volume.
When is Cytokinetics, Incorporated's next earnings date?
CYTK's next earnings report is estimated for 2026-11-04 — about 22 days away.
What is the analyst price target for CYTK?
The consensus analyst price target for CYTK is $114.56, about 82.4% above the current $62.79. Over the past 90 days, analysts recorded 0 upgrades, 8 maintains, and 0 downgrades.
How BestStocks tracks CYTK
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for CYTK, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 13, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
